On June 9, 2011, the Compensation Committee of the Board of Directors (the "Board") of Alnylam Pharmaceuticals, Inc. (the "Company") approved an increase in annual base salary for John M. Maraganore, Ph.D., the Company's Chief Executive Officer, from $525,000 to $650,000, effective immediately. Dr. Maraganore's annual base salary had not been increased since January 2008 and was increased at this time to be more competitive with salaries within the 50th and 60th percentiles for similar positions in the Company's industry peer group.
wanna bet they don't decrease his salary now that the company is much smaller and has different peers.
rnai_inv would you agree that he earned his strips with the recent run in the stock price? Company has gone from near death situation to sustained investor interest. One thing I am wondering is that he does not get much options. Is his contract backend loaded? To give him incentive to bring a drug, hopefully the first of its kind, thru all clinical phases and to the market.
Maraganore has really limited upside potential in this stock. just talk to all the shareholder who bought at $25+. They could have sold the company for $30+ years ago, easily, they could have bought TKMR, they could have done more deals and partnerships, they could have settled the lawsuits already. But no mr maraganore is only interested in his own job. The clinical results with TTR and PCS have had much to do with the run up. He has his qualities, but seriously, I have seen much better CEOs
Stock Option (right to buy) $7.1 11/30/2011 A 150,000 (1) 11/30/2021